Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2003409 | 0.86 | KMT2A (0.48) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL30456594 | 0.81 | KMT2A (0.30) | KMT2A | |
| SCHEMBL30456802 | 0.75 | — | — | |
| SCHEMBL14816146 | 0.70 | ADORA2A (0.36) | KMT2A | |
| SCHEMBL298837 | 0.70 | ALDH1A1 (0.44) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL2011359 | 0.69 | BRD4 (0.39) | — | |
| SCHEMBL1642605 | 0.68 | KMT2A (0.49) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL16825437 | 0.68 | DRD2 (0.36) | KMT2AMEN1FPR2PROKR1 | |
| SCHEMBL4760209 | 0.67 | KMT2A (0.47) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL3145134 | 0.67 | KMT2A (0.48) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | KMT2A 1139/4885MEN1 3518/4885POLB 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.